Sec Form 3 Filing - Jackman Stephan @ Alzamend Neuro, Inc. - 2021-06-14

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Jackman Stephan 2. Issuer Name and Ticker or Trading Symbol Alzamend Neuro, Inc. [ ALZN] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Executive Officer (Last) (First) (Middle) 3802 SPECTRUM BOULEVARD, SUITE 112C 3. Date of Earliest Transaction (MM/DD/YY) 06/14/2021 (Street) TAMPA, FL33612 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Options (right to buy) $ 1.5 ( 1 ) 11/18/2029 Common Stock 2,000,000 D Stock Options (right to buy) $ 1 ( 2 ) 11/15/2029 Common Stock 5,000,000 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Jackman Stephan 3802 SPECTRUM BOULEVARD, SUITE 112C TAMPA, FL33612 X Chief Executive Officer Signatures /s/ Stephan Jackman 06/14/2021 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The Reporting Person's right to exercise this stock option is subject to contingent vesting based upon either (i) the successful achievement of stepped target closing prices on a national securities exchange for 90 consecutive trading days later than 180 days after our initial public offering of our common stock, or (ii) stepped target prices for a change in control transaction. Of this stock option, no shares of Common Stock are currently vested and exercisable. ( 2 )Mr. Jackman was granted stock options (the "Options") to purchase 5,000,000 shares of the Issuer's Common Stock which Options are exercisable for a period of ten years beginning on November 16, 2018, at a per share price of $1.00, and vests as follows: (i) 3,000,000 shares of Common Stock will vest ratably over 48 months beginning on November 16, 2018; (ii) upon approval by the U.S. Food and Drug Administration ("FDA") of the New Drug Application ("NDA") for AL001, 1,000,000 shares of Common Stock will vest ratably over 36 months from November 1, 2018; and (iii) upon approval by the FDA of an NDA for AL002, 1,000,000 shares of Common Stock will vest ratably over 48 months from November 1, 2018. Of this stock option, 2,000,000 shares are currently vested and exercisable.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.